Table 2:
Novel Immunotherapeutic agents in multiple myeloma
| Agent | Class | Target | ClinicalTrials.gov Identifier | Clinical Phase | Single/Combination |
|---|---|---|---|---|---|
| Anti-CD38 CAR-T | Cellular | CAR-T CD 38 | NCT03464916 | Phase 1 | Single |
| bb21217 | Cellular | CAR-T BCMA | NCT03274219 | Phase 1 | Single |
| KITE-585 | Cellular | CAR-T BCMA | NCT03318861 | Phase 1 | Single |
| Kymriah | Cellular | CAR-T CD19 | NCT02529813 | Phase 1 | Single |
| NAM-NK Cells | Cellular | NK Cells | NCT03019666 | Phase 1 | Single |
| P-BCMA-101 | Cellular | CAR-T BCMA | NCT03288493 | Phase 1 | Single |
| PNK-007 | cellular | Natural Killer Cell | NCT02955550 | Phase 1 | Single |
| CYAD-01 | Cellular | CAR-T-NKG2D | NCT02203825 | Phase 1 | Single |
| AUTO2 | Cellular | CAR-T BCMA | NCT03287804 | Phase1–2 | Single |
| JCARH125 | Cellular | CAR-T BCMA | NCT03430011 | Phase1–2 | Single |
| LCAR-B38M | Cellular | CAR-T BCMA | NCT03090659 | Phase1–2 | Single |
| bb2121 | Cellular | CAR-T BCMA | NCT03361748, NCT03601078, NCT02658929 | Phase 2 | Single |
| AMG 424 | Mab-bi | CD3-CD38 | NCT03445663 | Phase 1 | Single |
| CJM112 | Mab | IL-17 | NCT03111992 | Phase 1 | Single and combination |
| DKN-01 | Mab | Dickkopf-1 (DKK-1) | NCT01457417 | Phase 1 | Single |
| JNJ-64007957 | Mab-bi | CD3-BCMA | NCT03145181 | Phase 1 | Single |
| JNJ-64407564 | Mab-bi | CD3-GPRC5D | NCT03399799 | Phase 1 | Single |
| Lirilumab | Mab | KIR | NCT02252263 | Phase 1 | Combination with Elotuzumab |
| MEDI2228 | Mab | Antibody-drug Conjugate anti BCMA | NCT03489525 | Phase 1 | Single |
| PF-06863135 | Mab-bi | CD3-BCMA | NCT03269136 | Phase 1 | Single |
| SEA-BCMA | Mab | BCMA | NCT03582033 | Phase 1 | Single |
| SGN-CD48A | Mab | Antibody-drug Conjugate anti CD48 | NCT03379584 | Phase 1 | Single |
| STRO-001 | Mab | Antibody-drug Conjugate anti CD74 | NCT03424603 | Phase 1 | Single |
| AMG 701 | Mab-bi | CD-3 BCMA | NCT03287908 | Phase 1 | Single |
| CC-93269 | Mab-bi | CD-3 BCMA | NCT03486067 | Phase 1 | Single |
| BION-1301 | Mab | APRIL | NCT03340883 | Phase1–2 | Single |
| BT-062 | Mab | Antibody-drug Conjugate anti CD 138 | NCT01001442, NCT01638936 | Phase1–2 | Single and combination with Len or Pom and Dex |
| MOR202 | Mab | CD38 | NCT01421186 | Phase1–2 | Combination with Dex and Len or Pom |
| TAK-079 | Mab | CD38 | NCT03439280 | Phase 1–2 | Single |
| TAK-573 | Mab | CD38 | NCT03215030 | Phase1–2 | Single |
| BHQ880 | Mab | Dickkopf-1 (DKK-1) | NCT01302886, NCT01337752 | Phase 2 | Single |
| GSK2857916 | Mab | Antibody-drug Conjugate anti BCMA | NCT03525678 | Phase 2 | Single |
| ABBV-838 | Mab | Antibody-drug Conjugate anti anti CS1 | NCT02462525 | Phase 1 | Combination with Pom and Dex |
| ImMucin | Peptide | Mucin 1 | NCT01232712 | Phase1–2 | Single |
| PVX-410 | Peptide | Vaccine | NCT02886065 | Phase 1 | Combination with Citarinostat and lenalidomide |
Novel Immunotherapeutic agents in multiple myeloma and stage of ongoing clinical trials (Mab= monoclonal antibody, Mab-bi=monoclonal antibody bispecific, Dex=dexamethasone, Len= lenalidomide, Pom=pomalidomide)